[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 51
1. Vachani A, Moon E, Wakeam E, Haas AR, Sterman DH, Albelda SM: Gene therapy for lung neoplasms. Clin Chest Med; 2011 Dec;32(4):865-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both advanced-stage lung cancer and malignant pleural mesothelioma are associated with a poor prognosis.
  • [MeSH-major] Genetic Therapy / methods. Lung Neoplasms / therapy. Mesothelioma / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Elsevier Inc. All rights reserved.
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):64-71 [19104515.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5 [19211796.001]
  • [Cites] PLoS One. 2009;4(5):e5445 [19421328.001]
  • [Cites] J Zhejiang Univ Sci B. 2009 May;10(5):331-40 [19434759.001]
  • [Cites] Cancer Gene Ther. 2009 Aug;16(8):620-4 [19287371.001]
  • [Cites] Ai Zheng. 2009 Dec;28(12):1324-7 [19958629.001]
  • [Cites] Hum Gene Ther. 2005 Sep;16(9):1016-27 [16149900.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1428-34 [16549837.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1689-99 [16505415.001]
  • [Cites] Lung Cancer. 2006 May;52(2):173-80 [16507327.001]
  • [Cites] Cancer Gene Ther. 2006 Jun;13(6):555-62 [16410826.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5527-36 [16740684.001]
  • [Cites] Mol Ther. 2006 Jun;13(6):1185-91 [16581300.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1160-6 [16998485.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4721-30 [16966690.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Nov;3(11):633-9 [17080181.001]
  • [Cites] J Clin Invest. 2007 Jun;117(6):1466-76 [17549249.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4456-66 [17671130.001]
  • [Cites] Mol Biotechnol. 2007 May;36(1):71-80 [17827541.001]
  • [Cites] Eur J Immunol. 2010 Feb;40(2):494-504 [19950185.001]
  • [Cites] Blood. 2010 Feb 4;115(5):925-35 [19880495.001]
  • [Cites] Mol Ther. 2010 Apr;18(4):852-60 [20068553.001]
  • [Cites] J Natl Cancer Inst. 2010 Aug 4;102(15):1108-10 [20668267.001]
  • [Cites] N Engl J Med. 2010 Aug 19;363(8):711-23 [20525992.001]
  • [Cites] Am J Respir Crit Care Med. 2011 Dec 15;184(12):1395-9 [21642245.001]
  • [Cites] Ann Surg Oncol. 2005 Oct;12(10):825-30 [16132372.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7444-53 [16243818.001]
  • [Cites] J Pathol. 2006 Jan;208(2):299-318 [16362990.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):878-87 [16467102.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2227-36 [10561280.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):609-22 [10653876.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1626-31 [10815879.001]
  • [Cites] Cancer Gene Ther. 2000 May;7(5):663-70 [10830713.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2000;29:27-47 [10940242.001]
  • [Cites] Ann Thorac Surg. 2000 Aug;70(2):407-11 [10969653.001]
  • [Cites] Hum Gene Ther. 2000 Sep 1;11(13):1911-20 [10986563.001]
  • [Cites] Cancer Immunol Immunother. 2000 Nov;49(9):504-14 [11092617.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1865-70; discussion 1870-1 [11156085.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):289-98 [11208818.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1750-8 [11251006.001]
  • [Cites] Cancer Gene Ther. 2000 Dec;7(12):1511-8 [11228529.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1214-20 [11350886.001]
  • [Cites] Gene Ther. 2001 May;8(10):746-59 [11420638.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6201-12 [11507073.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(17):2194-8 [11677106.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):539-45 [12056703.001]
  • [Cites] Mol Ther. 2002 Aug;6(2):210-8 [12161187.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1647-52 [12457277.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):93-101 [12538456.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):624-30 [12586798.001]
  • [Cites] Gene Ther. 2003 Mar;10(5):386-95 [12601393.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jan;127(1):123-30 [14752422.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):592-601 [14726502.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):326-31 [14970281.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1110-7 [15020613.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2800-7 [15254047.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6086-93 [15447994.001]
  • [Cites] Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4 [2847285.001]
  • [Cites] J Leukoc Biol. 1994 Aug;56(2):203-9 [8071596.001]
  • [Cites] Anticancer Res. 1996 Jul-Aug;16(4A):1993-8 [8712732.001]
  • [Cites] Nat Med. 1996 Sep;2(9):985-91 [8782455.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1857-63 [8961977.001]
  • [Cites] Hum Gene Ther. 1998 May 1;9(7):1083-92 [9607419.001]
  • [Cites] Hum Gene Ther. 1998 Sep 20;9(14):2075-82 [9759934.001]
  • [Cites] J Natl Cancer Inst. 1999 May 5;91(9):763-71 [10328106.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):720-31 [15613691.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3017-24 [15837756.001]
  • [Cites] Invest New Drugs. 2005 Jun;23(3):263-9 [15868384.001]
  • [Cites] Cancer Gene Ther. 2007 Nov;14(11):885-93 [17704755.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):870-6 [18281659.001]
  • [Cites] J Thorac Oncol. 2008 Apr;3(4):327-30 [18379348.001]
  • [Cites] N Engl J Med. 2008 May 22;358(21):2240-8 [18441370.001]
  • [Cites] Lancet. 2008 Jun 14;371(9629):2044-7 [18555917.001]
  • [Cites] Mol Ther. 2008 Jul;16(7):1189-99 [18500252.001]
  • [Cites] J Thorac Oncol. 2008 Jul;3(7):735-44 [18594319.001]
  • [Cites] J Transl Med. 2008;6:38 [18644162.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4166-71 [18757331.001]
  • [Cites] Clin Microbiol Rev. 2008 Oct;21(4):583-93 [18854481.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Nov;5(11):1231-40 [18976133.001]
  • [Cites] Curr Gene Ther. 2008 Dec;8(6):438-48 [19075627.001]
  • [Cites] Curr Gene Ther. 2008 Dec;8(6):474-82 [19075630.001]
  • [Cites] J Int Med Res. 2008 Nov-Dec;36(6):1273-8 [19094436.001]
  • (PMID = 22054892.001).
  • [ISSN] 1557-8216
  • [Journal-full-title] Clinics in chest medicine
  • [ISO-abbreviation] Clin. Chest Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K07 CA111952; United States / NCI NIH HHS / CA / P01 CA066726; United States / NCI NIH HHS / CA / P01 CA066726-14; United States / NCI NIH HHS / CA / P01 CA66726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS330385; NLM/ PMC3210443
  •  go-up   go-down


2. Birnie KA, Prêle CM, Thompson PJ, Badrian B, Mutsaers SE: Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma. Oncotarget; 2017 Sep 29;8(44):78193-78207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.
  • Malignant mesothelioma is an aggressive and often fatal cancer associated with asbestos exposure.
  • The disease originates in the mesothelial lining of the serosal cavities, most commonly affecting the pleura.
  • Survival rates are low as diagnosis often occurs at an advanced stage and current treatments are limited.
  • Identifying new diagnostic and therapeutic targets for mesothelioma remains a priority, particularly for the new wave of victims exposed to asbestos through do-it-yourself renovations and in countries where asbestos is still mined and used.
  • Recent advances have demonstrated a biological role for the small but powerful gene regulators microRNA (miRNA) in mesothelioma.
  • MiRNA have also become popular as potential biomarkers for mesothelioma due to their stable expression in bodily fluid and tissues.
  • In this review, we highlight the current challenges associated with the diagnosis and treatment of mesothelioma and discuss how targeting miRNA may improve diagnostic, prognostic and therapeutic approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2012 Nov;142(5):1267-1273 [22576637.001]
  • [Cites] Int J Clin Oncol. 2012 Feb;17 (1):40-7 [22237727.001]
  • [Cites] Front Pharmacol. 2015 Jun 09;6:113 [26106328.001]
  • [Cites] PLoS One. 2017 Jan 26;12 (1):e0170999 [28125734.001]
  • [Cites] Mutat Res. 2011 Dec 1;717(1-2):85-90 [21402084.001]
  • [Cites] Curr Opin Pulm Med. 2009 Jul;15(4):366-70 [19417672.001]
  • [Cites] Am J Cancer Res. 2016 Sep 01;6(9):1996-2009 [27725905.001]
  • [Cites] Wien Klin Wochenschr. 2016 Sep;128(17-18):618-26 [27457872.001]
  • [Cites] Sci Rep. 2017 Jun 9;7(1):3140 [28600498.001]
  • [Cites] Inhal Toxicol. 2006 Nov;18(12):995-1000 [16920674.001]
  • [Cites] J Gastrointest Oncol. 2016 Feb;7(1):79-86 [26941986.001]
  • [Cites] Int J Clin Exp Pathol. 2012;5(5):472-8 [22808303.001]
  • [Cites] Ann Oncol. 2013 Dec;24(12):3128-35 [24148817.001]
  • [Cites] J Cell Physiol. 2010 Mar;222(3):540-5 [20020507.001]
  • [Cites] Eur Respir J. 1998 Oct;12(4):972-81 [9817178.001]
  • [Cites] Intern Med J. 2010 Nov;40(11):742-50 [20298508.001]
  • [Cites] Curr Opin Biotechnol. 2011 Dec;22(6):909-16 [21550793.001]
  • [Cites] Chest. 2013 Nov;144(5):1632-1643 [23828229.001]
  • [Cites] Int J Cancer. 2010 Dec 15;127(12):2859-69 [21351265.001]
  • [Cites] Dis Markers. 2017;2017:9280170 [28321148.001]
  • [Cites] Int J Biol Sci. 2016 Oct 18;12 (11):1279-1288 [28090191.001]
  • [Cites] J Pathol. 2011 Jan;223(2):102-15 [21125669.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1A):39-44 [17352214.001]
  • [Cites] PLoS One. 2011 Apr 01;6(4):e18232 [21483773.001]
  • [Cites] Radiother Oncol. 2006 Jul;80(1):13-8 [16820238.001]
  • [Cites] Occup Environ Med. 2016 Mar;73(3):187-94 [26800709.001]
  • [Cites] Cancer Cell. 2007 May;11(5):431-45 [17482133.001]
  • [Cites] Cancer Res. 2010 Mar 1;70(5):1916-24 [20160038.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):615-23 [19396864.001]
  • [Cites] Mol Genet Genomics. 2010 Aug;284(2):95-103 [20596726.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):376-85 [15852042.001]
  • [Cites] Cancer Gene Ther. 2011 Nov;18(11):806-16 [21869823.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Radiol Med. 2016 Apr;121(4):253-60 [26661955.001]
  • [Cites] Semin Respir Crit Care Med. 2011 Feb;32(1):102-10 [21500129.001]
  • [Cites] Environ Health Prev Med. 2008 Mar;13(2):60-4 [19568882.001]
  • [Cites] Eur Respir J. 2013 Mar;41(3):706-15 [22835614.001]
  • [Cites] Oncotarget. 2015 Sep 15;6(27):23480-95 [26125439.001]
  • [Cites] Antioxid Redox Signal. 2014 Nov 20;21(15):2109-25 [24444362.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5547-51 [7923195.001]
  • [Cites] Eur Respir Rev. 2016 Dec;25(142):472-486 [27903668.001]
  • [Cites] Annu Rev Biochem. 2010;79:351-79 [20533884.001]
  • [Cites] Case Rep Oncol Med. 2013;2013:283601 [23840993.001]
  • [Cites] Methods Mol Biol. 2015;1218:365-73 [25319664.001]
  • [Cites] Mod Pathol. 2012 Jan;25(1):86-99 [21983934.001]
  • [Cites] Cancer Sci. 2012 Aug;103(8):1440-4 [22537085.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):9-16 [14592528.001]
  • [Cites] Biomol Concepts. 2014 Aug;5(4):275-87 [25372759.001]
  • [Cites] Intern Med J. 2011 May;41(5):372-80 [21309996.001]
  • [Cites] Clin Chem. 2016 May;62(5):743-54 [27127244.001]
  • [Cites] Oncol Rep. 2013 Jun;29(6):2169-74 [23525472.001]
  • [Cites] Med J Aust. 2016 Feb 1;204(2):48-9 [26821092.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2016 Dec 20;36(12 ):1700-1705 [27998868.001]
  • [Cites] J Toxicol Sci. 2008 Feb;33(1):105-16 [18303189.001]
  • [Cites] Biosci Trends. 2017 Mar 22;11(1):105-109 [28133000.001]
  • [Cites] Anticancer Res. 2015 Nov;35(11):6223-9 [26504055.001]
  • [Cites] PLoS Genet. 2015 Dec 18;11(12 ):e1005633 [26683624.001]
  • [Cites] Invest New Drugs. 2017 Apr;35(2):180-188 [27917453.001]
  • [Cites] J Mol Diagn. 2014 Jul;16(4):418-30 [24912849.001]
  • [Cites] J Hematol Oncol. 2017 Jan 18;10 (1):19 [28100259.001]
  • [Cites] Ann Cardiothorac Surg. 2012 Nov;1(4):491-6 [23977542.001]
  • [Cites] J Mol Diagn. 2010 Nov;12(6):771-9 [20864637.001]
  • [Cites] Curr Treat Options Oncol. 2011 Jun;12(2):149-62 [21424750.001]
  • [Cites] Int J Oncol. 2016 Apr;48(4):1599-607 [26820394.001]
  • [Cites] Cancer Sci. 2015 Oct;106(10):1296-302 [26211743.001]
  • [Cites] Oncotarget. 2016 Apr 5;7(14 ):18713-21 [26918730.001]
  • [Cites] Mol Cancer Res. 2015 Jul;13(7):1106-18 [25824152.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Oncogene. 2014 Nov 13;33(46):5319-31 [24240684.001]
  • [Cites] Int J Colorectal Dis. 2014 Jul;29(7):891-2 [24777352.001]
  • [Cites] Am J Respir Cell Mol Biol. 2010 Mar;42(3):312-9 [19502386.001]
  • [Cites] Oncotarget. 2016 Jun 14;7(24):36338-36352 [27119351.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3508-15 [10589765.001]
  • [Cites] Med Oncol. 2014 Dec;31(12):303 [25358615.001]
  • [Cites] PLoS One. 2012;7(1):e30221 [22253921.001]
  • [Cites] J Thorac Oncol. 2012 Jul;7(7):1184-91 [22617246.001]
  • [Cites] Thorax. 1982 Nov;37(11):810-5 [7163998.001]
  • [Cites] Clin Chim Acta. 2014 Jun 10;433:44-8 [24607327.001]
  • [Cites] N Engl J Med. 2012 Oct 11;367(15):1417-27 [23050525.001]
  • [Cites] Mol Biol Cell. 2008 May;19(5):2003-13 [18305103.001]
  • [Cites] Science. 1982 Apr 30;216(4545):518-20 [7071597.001]
  • [Cites] Mol Cancer. 2016 Jun 01;15(1):44 [27245839.001]
  • [Cites] Cell. 2003 Oct 17;115(2):199-208 [14567917.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Cancer Cytopathol. 2016 Jan;124(1):28-37 [26765063.001]
  • [Cites] Front Genet. 2017 Mar 28;8:31 [28400788.001]
  • [Cites] J Thorac Oncol. 2017 Sep;12 (9):1421-1433 [28629895.001]
  • [Cites] Eur J Cardiothorac Surg. 2010 Mar;37(3):566-72 [19781955.001]
  • [Cites] J Biol Chem. 2010 Jul 23;285(30):22809-17 [20463022.001]
  • [Cites] Oncotarget. 2016 Dec 13;7(50):82700-82711 [27716620.001]
  • [Cites] Chest. 1996 Jan;109(1):109-14 [8549169.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):591-600 [15864305.001]
  • [Cites] J Mol Diagn. 2000 Nov;2(4):209-16 [11232111.001]
  • [Cites] Cancer Causes Control. 2009 Oct;20(8):1237-54 [19444627.001]
  • [Cites] Biochem Pharmacol. 2017 Jan 1;123:8-18 [27431778.001]
  • [Cites] Int J Nanomedicine. 2013;8:4481-94 [24293999.001]
  • [Cites] Stem Cell Reports. 2017 Apr 11;8(4):1005-1017 [28285878.001]
  • [Cites] Br J Cancer. 2011 Apr 12;104(8):1325-33 [21448170.001]
  • [Cites] PLoS One. 2009;4(2):e4395 [19198648.001]
  • [Cites] J Natl Compr Canc Netw. 2012 Jan;10(1):49-57 [22223869.001]
  • [Cites] J Clin Pathol. 2012 Jan;65(1):77-82 [22081786.001]
  • [Cites] Cell. 2006 Jun 2;125(5):887-901 [16751099.001]
  • [Cites] Epigenomics. 2016 Aug;8(8):1079-85 [27185582.001]
  • [Cites] Oncotarget. 2016 Dec 20;7(51):84851-84859 [27769044.001]
  • [Cites] EBioMedicine. 2016 Oct;12 :34-42 [27720213.001]
  • [Cites] Trends Genet. 2017 Mar;33(3):208-219 [28174021.001]
  • [Cites] J Surg Res. 2015 Jun 1;196(1):23-32 [25791825.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):740-4 [15973356.001]
  • [Cites] Arch Pathol Lab Med. 2012 Mar;136(3):277-93 [22372904.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Cytojournal. 2015 Nov 30;12:26 [26681974.001]
  • [Cites] J Clin Gastroenterol. 2013 Sep;47(8):684-8 [23685846.001]
  • [Cites] Int J Oncol. 2017 Mar;50(3):1029-1034 [28197633.001]
  • [Cites] Respirology. 2002 Sep;7(3):171-91 [12153683.001]
  • [Cites] Oncotarget. 2016 Sep 6;7(36):58606-58637 [27259231.001]
  • [Cites] Eur Respir Rev. 2015 Mar;24(135):115-31 [25726562.001]
  • [Cites] Cancer Causes Control. 2016 Dec;27(12 ):1487-1489 [27812913.001]
  • [Cites] Clin Cancer Res. 2011 Aug 1;17(15):4965-74 [21673066.001]
  • [Cites] Int J Colorectal Dis. 2015 Jan;30(1):1-10 [25331029.001]
  • [Cites] Anticancer Res. 2012 Nov;32(11):4871-5 [23155254.001]
  • [Cites] Tumori. 2005 Sep-Oct;91(5):394-400 [16459635.001]
  • [Cites] Ther Adv Respir Dis. 2016 Jun;10(3):275-88 [26873306.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Mol Oncol. 2015 Mar;9(3):715-26 [25497279.001]
  • (PMID = 29100460.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; biomarkers / malignant peritoneal mesothelioma / malignant pleural mesothelioma / microRNA / therapies
  •  go-up   go-down


3. Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Biello F, Barletta G, Merlo DF, Valentino A, Ferro P, Ravetti GL, Stigliani S, Vigani A, Fedeli F, Beer DG, Roncella S, Grossi F: Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. Oncotarget; 2017 Sep 15;8(40):68627-68640
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal overall survival (OS) and to date no molecular markers are available to guide patient management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Lett. 2013 Oct;6(4):1025-1030 [24137458.001]
  • [Cites] Lancet. 2016 Apr 2;387(10026):1405-1414 [26719230.001]
  • [Cites] Microrna. 2016;5(1):12-18 [26817512.001]
  • [Cites] Mol Med Rep. 2015 Feb;11(2):1469-75 [25352177.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Oral Oncol. 2012 Aug;48(8):686-91 [22425712.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):810-8 [18523997.001]
  • [Cites] Ann Cardiothorac Surg. 2012 Nov;1(4):516-22 [23977546.001]
  • [Cites] Genom Data. 2016 Jun 20;9:44-9 [27408810.001]
  • [Cites] Int J Cancer. 2010 Dec 15;127(12):2859-69 [21351265.001]
  • [Cites] Oncogene. 2014 Mar 13;33(11):1448-57 [23503464.001]
  • [Cites] Cancer Res. 2010 Mar 1;70(5):1916-24 [20160038.001]
  • [Cites] Front Physiol. 2015 Feb 04;6:10 [25698970.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):615-23 [19396864.001]
  • [Cites] J Biol Chem. 2012 Jan 6;287(2):1527-37 [22128178.001]
  • [Cites] Oncogene. 2016 Jun 30;35(26):3376-86 [26455324.001]
  • [Cites] BMC Cancer. 2009 Dec 15;9:441 [20003513.001]
  • [Cites] Biomol Detect Quantif. 2016 May 27;10 :15-23 [27990345.001]
  • [Cites] Expert Opin Pharmacother. 2016 Jun;17 (9):1197-205 [27055148.001]
  • [Cites] Nucleic Acids Res. 2016 Jan 4;44(D1):D239-47 [26590260.001]
  • [Cites] PLoS One. 2014 Jul 22;9(7):e102403 [25050621.001]
  • [Cites] J Mol Diagn. 2010 Nov;12(6):771-9 [20864637.001]
  • [Cites] Oncotarget. 2016 Apr 5;7(14 ):18713-21 [26918730.001]
  • [Cites] Am J Respir Cell Mol Biol. 2010 Mar;42(3):312-9 [19502386.001]
  • [Cites] J Thorac Oncol. 2011 May;6(5):844-51 [21358347.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Nat Rev Cancer. 2012 Oct;12 (10 ):721-32 [22996602.001]
  • [Cites] Br J Cancer. 2012 Jun 26;107(1):161-4 [22644294.001]
  • [Cites] Cell Mol Life Sci. 2014 Aug;71(15):2865-78 [24562347.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Cell Physiol Biochem. 2016;39(2):501-10 [27383536.001]
  • [Cites] Transl Lung Cancer Res. 2015 Feb;4(1):55-66 [25806346.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Mol Oncol. 2015 Mar;9(3):715-26 [25497279.001]
  • (PMID = 28978143.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; malignant pleural mesothelioma / miR-99a/let-7c/miR-125b miRNAs cluster / miRNA signature / prognostic biomarkers / unresectable tumors
  •  go-up   go-down


Advertisement
4. Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F: Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. Oncol Lett; 2016 12;12(6):4505-4509
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.
  • Diffuse malignant pleural mesothelioma (MPM) is an aggressive tumor that originates from the surface of the pleura.
  • The majority of patients with pancreatic cancer are diagnosed with an advanced stage of disease and experience a poor response to therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2012;17(8):1100-7 [22723509.001]
  • [Cites] Rev Esp Enferm Dig. 2010 Oct;102(10 ):602-3 [21039070.001]
  • [Cites] Eur J Cancer Prev. 2008 Nov;17(6):525-34 [18941374.001]
  • [Cites] Cancer Res Treat. 2008 Jun;40(2):97-9 [19688056.001]
  • [Cites] Ann Transl Med. 2015 Aug;3(13):182 [26366399.001]
  • [Cites] Thorax. 2000 Sep;55(9):731-5 [10950889.001]
  • [Cites] N Engl J Med. 2010 Apr 29;362(17):1605-17 [20427809.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):159-63 [19822288.001]
  • [Cites] World J Gastroenterol. 2012 Sep 7;18(33):4457-65 [22969215.001]
  • [Cites] JOP. 2013 Nov 10;14(6):686-8 [24216565.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3007-13 [19364962.001]
  • [Cites] N Engl J Med. 2013 Oct 31;369(18):1691-703 [24131140.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Histopathology. 2003 Oct;43(4):387-92 [14511258.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2577-82 [10375105.001]
  • [Cites] Lung Cancer. 2009 Jan;63(1):94-7 [18486273.001]
  • [Cites] World J Gastroenterol. 2010 Aug 21;16(31):3984-6 [20712062.001]
  • [Cites] World J Gastroenterol. 2014 Mar 7;20(9):2352-7 [24605032.001]
  • [Cites] Pathol Res Pract. 2006;202(8):617-22 [16814945.001]
  • [Cites] Biochim Biophys Acta. 2011 Apr;1814(4):513-22 [21338716.001]
  • [Cites] Radiat Oncol. 2010 Jul 08;5:64 [20615227.001]
  • [Cites] CA Cancer J Clin. 2013 Jan;63(1):11-30 [23335087.001]
  • [Cites] Ann Oncol. 2014 Feb;25(2):467-71 [24355488.001]
  • [Cites] Tumori. 2007 Jan-Feb;93(1):19-22 [17455866.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2009 Feb;47(2):133-8 [19260537.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] JOP. 2013 Mar 10;14(2):129-32 [23474553.001]
  • [Cites] Intern Med. 2010;49(6):597-601 [20228599.001]
  • [Cites] J Clin Oncol. 2011 Dec 1;29(34):4548-54 [21969517.001]
  • [Cites] Am J Surg. 2008 Sep;196(3):e1-2 [18513686.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] J Formos Med Assoc. 2008 Dec;107(12 ):961-4 [19129058.001]
  • [Cites] J Thorac Dis. 2014 May;6 Suppl 2:S238-52 [24868442.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • (PMID = 28105159.001).
  • [ISSN] 1792-1074
  • [Journal-full-title] Oncology letters
  • [ISO-abbreviation] Oncol Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Keywords] NOTNLM ; diffuse malignant pleural mesothelioma (major topic) / multimodal chemoradiotherapic approach (major topic) / pancreatic cancer (major topic) / stereotactic body radiation therapy (major topic) / synchronous tumors (major topic)
  •  go-up   go-down


5. Porpodis K, Zarogoulidis P, Boutsikou E, Papaioannou A, Machairiotis N, Tsakiridis K, Katsikogiannis N, Zaric B, Perin B, Huang H, Kougioumtzi I, Spyratos D, Zarogoulidis K: Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis; 2013 Sep;5 Suppl 4:S397-406
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: current and future perspectives.
  • Mesothelioma still remains an occupational related cancer with severe outcome.
  • It is usually diagnosed at advanced stage since it does not demonstrate early symptoms.
  • Several efforts have been made towards removing all materials inducing mesothelioma in the work setting and new work protection measures have been applied.
  • Although we have new targeted treatments and radical surgery as arrows in the quiver, the type of mesothelioma and early diagnosis still remain the best treatment approach.
  • In the current review we will present current data for mesothelioma and future perspectives.

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for malignant pleural mesothelioma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24102013.001).
  • [ISSN] 2072-1439
  • [Journal-full-title] Journal of thoracic disease
  • [ISO-abbreviation] J Thorac Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3791499
  • [Keywords] NOTNLM ; Mesothelioma / diagnosis / pathogenesis / targeted treatment / treatment
  •  go-up   go-down


6. Mott FE: Mesothelioma: a review. Ochsner J; 2012;12(1):70-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma: a review.
  • Mesothelioma is an insidious disease with long latency after asbestos exposure.
  • Treatment for early stage disease with surgery and radiation is potentially curative, but many patients either are too ill to undergo aggressive surgery or present with advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22438785.001).
  • [ISSN] 1524-5012
  • [Journal-full-title] The Ochsner journal
  • [ISO-abbreviation] Ochsner J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3307510
  • [Keywords] NOTNLM ; Asbestos / diagnosis / malignant pleural mesothelioma / targeted therapies / treatment
  •  go-up   go-down


7. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE: Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol; 2012 Jul 10;30(20):2509-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
  • PURPOSE: Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase II trials have reported variable outcomes.
  • CONCLUSION: The addition of bevacizumab to gemcitabine/cisplatin in this trial did not significantly improve PFS or OS in patients with advanced MM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy. Pleural Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] Chest. 1998 Mar;113(3):723-31 [9515850.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3B):2063-8 [9677468.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):25-30 [10458214.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2000 Dec 21;343(25):1846-50 [11117976.001]
  • [Cites] J Pathol. 2001 Apr;193(4):468-75 [11276005.001]
  • [Cites] Lung Cancer. 2005 May;48(2):291-6 [15829331.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):223-6 [15923792.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7199-206 [16192604.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1137-45, viii [16325128.001]
  • [Cites] Lung Cancer. 2006 Sep;53(3):367-74 [16828196.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] Lung Cancer. 2008 May;60(2):259-63 [18006112.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):263-73 [18772115.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5422-8 [18936475.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2081-90 [19255316.001]
  • [Cites] Lung Cancer. 2009 Jun;64(3):308-13 [19004520.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3073-6 [19451415.001]
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3617-22 [20606091.001]
  • [Cites] Ann Oncol. 2010 Sep;21(9):1804-9 [20150572.001]
  • [Cites] J Thorac Oncol. 2010 Oct;5(10):1655-61 [20736856.001]
  • [Cites] Br J Cancer. 2011 Feb 1;104(3):413-8 [21245868.001]
  • [Cites] Semin Respir Crit Care Med. 2011 Feb;32(1):102-10 [21500129.001]
  • [Cites] Lung Cancer. 2012 Jun;76(3):393-6 [22197613.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):70-6 [11836671.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):342-5 [11875695.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):491-6 [12189542.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Control Clin Trials. 1987 Dec;8(4):327-37 [3327653.001]
  • (PMID = 22665541.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / N01CM62209
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Humanized; 0 / Placebos; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC3397785
  •  go-up   go-down


8. Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR: SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol; 2015 Feb;10(2):387-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).
  • INTRODUCTION: The PI3K/Akt/mammalian target of rapamycin pathway is activated in a majority of malignant pleural mesotheliomas (MPM).
  • CONCLUSION: Everolimus has limited clinical activity in advanced MPM patients.
  • Additional studies of single-agent everolimus in advanced MPM are not warranted.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Sirolimus / analogs & derivatives

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2013 Jul;1291:14-32 [23659703.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4235-49 [19451229.001]
  • [Cites] Oncogene. 2005 Sep 8;24(40):6080-9 [15897870.001]
  • [Cites] J Thorac Oncol. 2011 Mar;6(3):598-601 [21270668.001]
  • [Cites] J Thorac Cardiovasc Surg. 2010 May;139(5):1233-40 [19853261.001]
  • [Cites] Mol Med Rep. 2009 Mar-Apr;2(2):181-8 [21475810.001]
  • [Cites] J Thorac Oncol. 2014 Feb;9(2):239-47 [24419422.001]
  • [Cites] Lung Cancer. 2009 May;64(2):140-7 [18835652.001]
  • [Cites] J Biol Chem. 2008 May 9;283(19):13021-30 [18339627.001]
  • [Cites] J Cell Biochem. 2009 Nov 1;108(4):867-76 [19718660.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2406-13 [17557954.001]
  • [Cites] Eur J Cancer. 2009 Sep;45(13):2304-11 [19502050.001]
  • [Cites] Lung Cancer. 2012 Jul;77(1):192-8 [22459204.001]
  • [Cites] J Thorac Oncol. 2011 May;6(5):852-63 [21358348.001]
  • (PMID = 25611229.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA86780; United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / CA76462; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / P01 CA114047; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / N01 CA013612; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / U10 CA013612; United States / NCI NIH HHS / CA / R01 CA077429; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / U10 CA180846; United States / NCI NIH HHS / CA / U10 CA063848; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / CA16385; United States / NIEHS NIH HHS / ES / P30 ES013508; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA105409; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / CA114047; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / CA77429; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / U10 CA011083; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA180888; United States / NCI NIH HHS / CA / U10 CA180819; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / U10 CA045807
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9HW64Q8G6G / Everolimus; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus; Mesothelioma, Malignant
  • [Other-IDs] NLM/ NIHMS624038; NLM/ PMC4304604
  •  go-up   go-down


9. Gunatilake S, Brims FJ, Fogg C, Lawrie I, Maskell N, Forbes K, Rahman N, Morris S, Ogollah R, Gerry S, Peake M, Darlison L, Chauhan AJ: A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial. Trials; 2014;15:367
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial.
  • BACKGROUND: Malignant pleural mesothelioma is an incurable cancer caused by exposure to asbestos.
  • The United Kingdom has the highest death rate from mesothelioma in the world and this figure is increasing.
  • A study from the United States examining advanced lung cancer showed that early specialist palliative care input improved patient health related quality of life and depression symptoms 12 weeks after diagnosis.
  • While mesothelioma and advanced lung cancer share many symptoms and have a poor prognosis, oncology and palliative care services in the United Kingdom, and many other countries, vary considerably compared to the United States.
  • The aim of this trial is to assess whether regular early symptom control treatment provided by palliative care specialists can improve health related quality of life in patients newly diagnosed with mesothelioma.
  • A total of 174 patients with a new diagnosis of malignant pleural mesothelioma will be minimised with a random element in a 1:1 ratio to receive either 4 weekly regular early specialist symptom control care, or standard care.
  • This study aims to investigate whether early, regular specialist care input can result in significant health related quality of life gains for patients with mesothelioma and if this change in treatment model is cost-effective.
  • [MeSH-major] Lung Neoplasms / therapy. Mesothelioma / therapy. Palliative Care / methods. Pleural Neoplasms / therapy. Quality of Life. Referral and Consultation. Research Design

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2000 Apr;55(1):19-25 [10788684.001]
  • [Cites] Lancet. 2014 May 17;383(9930):1721-30 [24559581.001]
  • [Cites] Lung Cancer. 2001 Feb-Mar;31(2-3):233-40 [11165402.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Palliat Med. 2003 Oct;17(7):588-95 [14594149.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):587-95 [15274072.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3172-80 [15284270.001]
  • [Cites] Lancet. 1995 Mar 4;345(8949):535-9 [7776771.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] J Health Serv Res Policy. 1998 Oct;3(4):233-45 [10187204.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):587-93 [15668716.001]
  • [Cites] Thorax. 2007 Nov;62 Suppl 2:ii1-ii19 [17965072.001]
  • [Cites] Thorax. 2008 May;63(5):435-9 [18202164.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1175-83 [19259084.001]
  • [Cites] J R Nav Med Serv. 2009;95(1):4-11 [19425525.001]
  • [Cites] N Engl J Med. 2010 Aug 19;363(8):733-42 [20818875.001]
  • [Cites] J Pain Symptom Manage. 2011 Feb;41(2):456-68 [20832987.001]
  • [Cites] Clin Respir J. 2012 Jul;6(3):144-9 [21651745.001]
  • [Cites] JAMA. 2013 Nov 27;310(20):2191-4 [24141714.001]
  • [Cites] Soc Psychiatry Psychiatr Epidemiol. 2000 Nov;35(11):508-12 [11197926.001]
  • (PMID = 25238873.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN18955704
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Mesothelioma, Malignant
  • [Other-IDs] NLM/ PMC4180732
  •  go-up   go-down


10. Huang L, Cai M, Zhang X, Wang F, Chen L, Xu M, Yang K, Chen Z, Wang X, Fu L: Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma. Am J Cancer Res; 2017;7(2):203-217
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma.
  • Malignant pleural mesothelioma (MPM) is a relative rare but highly aggressive neoplasm which is associated with asbestos exposure in most patients.
  • The majority of patients are diagnosed in advanced stages so patients neither benefit from chemotherapy (e.g. pemetrexed-platinum combination) nor from surgery.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2014 Jun 28;14 :473 [24973959.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 [18089725.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):621-81 [16968952.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Ann Thorac Surg. 1987 Jan;43(1):113-20 [3541812.001]
  • [Cites] Biochem Soc Trans. 2016 Apr 15;44(2):363-70 [27068941.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Lung Cancer. 2013 Aug;81(2):155-61 [23664448.001]
  • [Cites] J Thorac Oncol. 2010 Oct;5(10):1692-703 [20802345.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] Thorax. 2014 Feb;69(2):194-7 [23760546.001]
  • [Cites] Carcinogenesis. 2009 Jul;30(7):1097-105 [19380521.001]
  • [Cites] Chin J Cancer. 2015 Aug 08;34(9):404-12 [26253541.001]
  • [Cites] Curr Probl Cancer. 2004 May-Jun;28(3):93-174 [15197388.001]
  • [Cites] Clin Cancer Res. 2012 Jul 15;18(14):3737-42 [22547770.001]
  • [Cites] Breast Cancer Res Treat. 2012 Jun;133(3):1057-65 [22418700.001]
  • [Cites] Cancer Biol Ther. 2006 Jan;5(1):39-47 [16319528.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Dec;9(12 ):1336-46 [19037840.001]
  • (PMID = 28337371.001).
  • [Journal-full-title] American journal of cancer research
  • [ISO-abbreviation] Am J Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; EGFR / MET / Malignant pleural mesothelioma / afatinib / crizotinib
  •  go-up   go-down






Advertisement